EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Treatment of dry age‐related macular degeneration: A review

Shenouda Girgis iD, Lawrence R Lee

Clinical & Experimental Ophthalmology · 2023-11 · 51 (8) · 835-852

DOI: 10.1111/ceo.14294 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 22.09.2023. Verfasst von Shenouda Girgis und 1 weiteren Autor:innen. Beteiligte Einrichtung: City Eye Centre, Brisbane, Australia. Hauptthemen laut MEDLINE: Geographic Atrophy, Macular Degeneration, Wet Macular Degeneration. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age‐related macular degeneration is a global disease with a significant societal impact. The advent of anti‐vascular endothelial growth factor therapy (anti‐VEGF) has revolutionised the treatment of neovascular age‐related macular degeneration (nAMD). Dry age‐related macular degeneration (dAMD) is being investigated for possible therapeutic options. The therapeutic categories undergoing clinical trials include complement pathway inhibitors, visual cycle modulators, reduction of toxic byproducts, antioxidative therapy, neuroprotective agents, laser therapy, surgical options, gene therapy, stem cell therapy, and miscellaneous treatments. Two intravitreal anti‐complement factors (pegcetacoplan and avacincaptad pegol) have recently shown phase 3 clinical trial evidence of a reduction in the growth of geographic atrophy. In this review, we provide an update on treatment options currently undergoing clinical research trials for the management of dAMD and preventing the progression of Geographic Atrophy (GA).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Geographic AtrophyMacular DegenerationWet Macular DegenerationHumansAngiogenesis InhibitorsIntravitreal Injections

Stichwörter der Autor:innen

age-related macular degeneration (AMD)complement inhibitorsdry age-related macular degeneration

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • City Eye Centre, Brisbane, Australia.
  • Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Faculty of Medicine, University of Queensland, Saint Lucia, Queensland, Australia.

ORCID-Profile: Shenouda Girgis

Zitieren

APA

Girgis, S., & Lee, L. R. (2023). Treatment of dry age‐related macular degeneration: A review. Clinical & Experimental Ophthalmology, 51(8), 835-852. https://doi.org/10.1111/ceo.14294

Vancouver

Girgis S, Lee LR. Treatment of dry age‐related macular degeneration: A review. Clinical & Experimental Ophthalmology. 2023;51(8):835-852. doi:10.1111/ceo.14294

BibTeX
@article{Girgis2023,
  author = {Girgis, Shenouda and Lee, Lawrence R},
  title = {Treatment of dry age‐related macular degeneration: A review},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2023},
  volume = {51},
  number = {8},
  pages = {835--852},
  doi = {10.1111/ceo.14294}
}
Kostenlos starten →